With regard to the high mutation rate and drug resistance of HIV, 'BiIA-SG' has the effect of 'one stone with two birds', binds to CD4 protein on the surface of host immune cells, can ambush HIV, and protects cells from being infected with HIV.
The team conducted a drug test on mice: It was found that after injection, healthy mice can prevent 124 subtypes of HIV, and antibodies can be maintained in the body for a week. In terms of treatment, HIV-infected mice have 42 genes after they are introduced into drugs. % mice suppress HIV in the body within 3 months and effectively reduce the amount of virus.
Chen Zhiwei said that the current methods commonly used for the treatment of AIDS, such as cocktail therapy, can suppress the number of viruses, but they need to be taken for life. Some patients may develop side effects such as drug resistance, cardiovascular diseases, and allergies. Once the drug is discontinued, the virus may recur. However, BilA-SG as a universally applicable antibody drug has greatly improved its broad spectrum and effectiveness.
The new drug was developed by the team from 2010. It is expected that clinical research on other large mammals, including humans, can be implemented as soon as possible. If BilA-SG can successfully pass clinical tests, BilA-SG is expected to be the first 'Made in Hong Kong' treatment of HIV. Antibody drug.
Using 'BilA-SG' can do a year to help healthy people avoid HIV infection and even become one of the prevention measures for high-risk people such as men who have sex with men.